Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Ideaya Biosciences Inc (IDYA)

Ideaya Biosciences Inc (IDYA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update PR Newswire - Tue Aug 4, 5:00AM CDT

SOUTH SAN FRANCISCO, Calif. , Aug. 4, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery, development and commercialization...

IDYA : 36.96 (+0.33%)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire - Fri Jul 31, 5:00AM CDT

SOUTH SAN FRANCISCO, Calif. , July 31, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...

IDYA : 36.96 (+0.33%)
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers PR Newswire - Mon Jul 27, 5:00AM CDT

SOUTH SAN FRANCISCO, Calif. , July 27, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that initiation of Part 2 monotherapy...

IDYA : 36.96 (+0.33%)
IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs PR Newswire - Fri Jul 17, 8:00AM CDT

SOUTH SAN FRANCISCO, Calif. , July 17, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced three abstract presentations at...

IDYA : 36.96 (+0.33%)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire - Fri Jun 26, 5:00AM CDT

SOUTH SAN FRANCISCO, Calif. , June 26, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted...

IDYA : 36.96 (+0.33%)
IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors PR Newswire - Wed Jun 17, 5:00AM CDT

SOUTH SAN FRANCISCO, Calif. , June 17, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that its Board of Directors has...

IDYA : 36.96 (+0.33%)
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire - Wed Jun 10, 3:05PM CDT

SOUTH SAN FRANCISCO, Calif. , June 10, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the closing of its underwritten public offering of 7,222,225 shares of its common...

IDYA : 36.96 (+0.33%)
Biotech research by Gorodenkoff via Shutterstock
Tango Therapeutics (TNGX) Stock Soars on Pancreatic Cancer Trial Results Barchart - Tue Jun 9, 8:29AM CDT

Tango Therapeutics shares rallied on Monday after recording impressive results for its pancreatic cancer drug. Here’s how you should play TNGX stock at current levels.

IDYA : 36.96 (+0.33%)
JNJ : 260.86 (+0.41%)
INCY : 120.77 (-0.25%)
TNGX : 25.58 (-2.89%)
RHHBY : 56.5100 (-0.19%)
IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants PR Newswire - Mon Jun 8, 9:22PM CDT

SOUTH SAN FRANCISCO, Calif. , June 8, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of an underwritten public offering of common stock and pre-funded warrants....

IDYA : 36.96 (+0.33%)
IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants PR Newswire - Mon Jun 8, 3:01PM CDT

SOUTH SAN FRANCISCO, Calif. , June 8, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced that it intends to offer and sell up to $300.0 million of shares of its common stock...

IDYA : 36.96 (+0.33%)

Barchart Exclusives

Target Appoints Its First-Ever AI Exec as the Retailer Pushes Deeper Into Artificial Intelligence. What It Means for TGT Stock. Barchart - 31 minutes ago
Target appointed Chandhu Nair as its first chief artificial intelligence officer, effective Aug. 24, as the retailer expands its use of AI across inventory, operations, and customer experience. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.